Direkt zum Inhalt
Merck
  • Stress disrupts intestinal mucus barrier in rats via mucin O-glycosylation shift: prevention by a probiotic treatment.

Stress disrupts intestinal mucus barrier in rats via mucin O-glycosylation shift: prevention by a probiotic treatment.

American journal of physiology. Gastrointestinal and liver physiology (2014-06-28)
Stéphanie Da Silva, Catherine Robbe-Masselot, Afifa Ait-Belgnaoui, Alessandro Mancuso, Myriam Mercade-Loubière, Christel Salvador-Cartier, Marion Gillet, Laurent Ferrier, Pascal Loubière, Etienne Dague, Vassilia Theodorou, Muriel Mercier-Bonin
ZUSAMMENFASSUNG

Despite well-known intestinal epithelial barrier impairment and visceral hypersensitivity in irritable bowel syndrome (IBS) patients and IBS-like models, structural and physical changes in the mucus layer remain poorly understood. Using a water avoidance stress (WAS) model, we aimed at evaluating whether 1) WAS modified gut permeability, visceral sensitivity, mucin expression, biochemical structure of O-glycans, and related mucus physical properties, and 2) whether Lactobacillus farciminis treatment prevented these alterations. Wistar rats received orally L. farciminis or vehicle for 14 days; at day 10, they were submitted to either sham or 4-day WAS. Intestinal paracellular permeability and visceral sensitivity were measured in vivo. The number of goblet cells and Muc2 expression were evaluated by histology and immunohistochemistry, respectively. Mucosal adhesion of L. farciminis was determined ex situ. The mucin O-glycosylation profile was obtained by mass spectrometry. Surface imaging of intestinal mucus was performed at nanoscale by atomic force microscopy. WAS induced gut hyperpermeability and visceral hypersensitivity but did not modify either the number of intestinal goblet cells or Muc2 expression. In contrast, O-glycosylation of mucins was strongly affected, with the appearance of elongated polylactosaminic chain containing O-glycan structures, associated with flattening and loss of the mucus layer cohesive properties. L. farciminis bound to intestinal Muc2 and prevented WAS-induced functional alterations and changes in mucin O-glycosylation and mucus physical properties. WAS-induced functional changes were associated with mucus alterations resulting from a shift in O-glycosylation rather than from changes in mucin expression. L. farciminis treatment prevented these alterations, conferring epithelial and mucus barrier strengthening.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Dimethylsulfoxid, Hybri-Max, sterile-filtered, BioReagent, suitable for hybridoma, ≥99.7%
Sigma-Aldrich
Dimethylsulfoxid, for molecular biology
Sigma-Aldrich
Dimethylsulfoxid, ACS reagent, ≥99.9%
Sigma-Aldrich
Dimethylsulfoxid, sterile-filtered, BioPerformance Certified, meets EP, USP testing specifications, suitable for hybridoma
Sigma-Aldrich
Dimethylsulfoxid, suitable for HPLC, ≥99.7%
Sigma-Aldrich
Dimethylsulfoxid, ReagentPlus®, ≥99.5%
Sigma-Aldrich
Dimethylsulfoxid, anhydrous, ≥99.9%
Sigma-Aldrich
Dimethylsulfoxid, ≥99.5% (GC), suitable for plant cell culture
Sigma-Aldrich
Dimethylsulfoxid, BioUltra, for molecular biology, ≥99.5% (GC)
Sigma-Aldrich
Dimethylsulfoxid, meets EP testing specifications, meets USP testing specifications
Sigma-Aldrich
Dimethylsulfoxid, PCR Reagent
USP
Dimethylsulfoxid, United States Pharmacopeia (USP) Reference Standard
Supelco
Dimethylsulfoxid, analytical standard
Supelco
Dimethylsulfoxid, for inorganic trace analysis, ≥99.99995% (metals basis)
Sigma-Aldrich
8-Octanoyloxypyren-1,3,6-Trisulfonsäure Trinatriumsalz, suitable for fluorescence, ≥90% (HPCE)
Dimethylsulfoxid, European Pharmacopoeia (EP) Reference Standard